Ryotaro Bouchi1, Tatsuya Fukuda2, Takato Takeuchi3, Yujiro Nakano4, Masanori Murakami5, Isao Minami6, Hajime Izumiyama7, Koshi Hashimoto8, Takanobu Yoshimoto9, Yoshihiro Ogawa10. 1. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: bouchi.mem@tmd.ac.jp. 2. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: fukuda.mem@tmd.ac.jp. 3. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: takeuchi.mem@tmd.ac.jp. 4. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: nakano.mem@tmd.ac.jp. 5. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: mmurakami.mem@tmd.ac.jp. 6. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: iminami.mem@tmd.ac.jp. 7. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University. Electronic address: hizumiyama.cme@tmd.ac.jp. 8. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; Department of Preemptive Medicine and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University. Electronic address: khashimoto.mem@tmd.ac.jp. 9. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: tyoshimoto.mem@tmd.ac.jp. 10. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; CREST, Japan Agency for Medical Research and Development, Tokyo, Japan. Electronic address: ogawa.mem@tmd.ac.jp.
Abstract
BACKGROUND: To investigate the association of both latent autoimmune diabetes in adults (LADA) and type 2 diabetes (T2DM) with muscle mass and function (sarcopenia). METHODS: Japanese patients with LADA (N=20), T2DM (N=208), and control subjects (N=41) were included in this cross-sectional study. The definition of LADA was based on age of onset (≥30), positive glutamic acid decarboxylase autoantibodies, and insulin requirement within the first 6months after diagnosis. Sarcopenia was diagnosed by the criteria for Asians, using skeletal muscle index (male <7.0 and female <5.4) and grip strength (male <26.0kg and female <18.0kg). The odds ratio (OR) with a 95% confidence interval (CI) was estimated using logistic regression. RESULTS: The prevalence of sarcopenia was higher in LADA (35.0%) than in either T2DM (13.3%) or control subjects (9.8%). LADA was significantly associated with an increased risk for sarcopenia in a multivariate model in which age and body mass index were incorporated (OR: 9.57, 95% CI: 1.86-49.27). In contrast, T2DM tended to be associated with an increased risk for sarcopenia (OR: 2.99, 95% CI: 0.83-10.80). CONCLUSIONS: This study provides evidence that patients with LADA are at a high risk for sarcopenia compared to those with T2DM or to control subjects.
BACKGROUND: To investigate the association of both latent autoimmune diabetes in adults (LADA) and type 2 diabetes (T2DM) with muscle mass and function (sarcopenia). METHODS: Japanese patients with LADA (N=20), T2DM (N=208), and control subjects (N=41) were included in this cross-sectional study. The definition of LADA was based on age of onset (≥30), positive glutamic acid decarboxylase autoantibodies, and insulin requirement within the first 6months after diagnosis. Sarcopenia was diagnosed by the criteria for Asians, using skeletal muscle index (male <7.0 and female <5.4) and grip strength (male <26.0kg and female <18.0kg). The odds ratio (OR) with a 95% confidence interval (CI) was estimated using logistic regression. RESULTS: The prevalence of sarcopenia was higher in LADA (35.0%) than in either T2DM (13.3%) or control subjects (9.8%). LADA was significantly associated with an increased risk for sarcopenia in a multivariate model in which age and body mass index were incorporated (OR: 9.57, 95% CI: 1.86-49.27). In contrast, T2DM tended to be associated with an increased risk for sarcopenia (OR: 2.99, 95% CI: 0.83-10.80). CONCLUSIONS: This study provides evidence that patients with LADA are at a high risk for sarcopenia compared to those with T2DM or to control subjects.
Authors: Lena Sophie Kiefer; Jana Fabian; Roberto Lorbeer; Jürgen Machann; Corinna Storz; Mareen Sarah Kraus; Elke Wintermeyer; Christopher Schlett; Frank Roemer; Konstantin Nikolaou; Annette Peters; Fabian Bamberg Journal: Br J Radiol Date: 2018-05-03 Impact factor: 3.039
Authors: Eberhard Lurz; Hiten Patel; Gerald Lebovic; Claudia Quammie; Jessica P Woolfson; Manuela Perez; Amanda Ricciuto; Paul W Wales; Binita M Kamath; Govind B Chavhan; Peter Jüni; Vicky L Ng Journal: J Cachexia Sarcopenia Muscle Date: 2020-01-09 Impact factor: 12.910
Authors: Hyo Jin An; Kalthoum Tizaoui; Salvatore Terrazzino; Sarah Cargnin; Keum Hwa Lee; Seoung Wan Nam; Jae Seok Kim; Jae Won Yang; Jun Young Lee; Lee Smith; Ai Koyanagi; Louis Jacob; Han Li; Jae Il Shin; Andreas Kronbichler Journal: Int J Mol Sci Date: 2020-08-07 Impact factor: 5.923